Beyond the SOLARIS study, Teva presented results from in vitro studies that evaluated TEV-'749 against the currently marketed intramuscular olanzapine long-acting injectable for the risk of PDSS, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback